Phase I trial of CC 359

Trial Profile

Phase I trial of CC 359

Phase of Trial: Phase I

Latest Information Update: 18 Feb 2014

At a glance

  • Drugs CC 359 (Primary)
  • Indications Reperfusion injury
  • Focus Adverse reactions
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 18 Feb 2014 Status changed from planning to discontinued.
    • 20 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top